Neurology coverage on this site has expanded rapidly as GLP-1 secondary indications keep appearing. AAN 2026 produced multiple readouts covered here: GLP-1 in chronic migraine (10% reduction in ED visits, 14% in hospitalizations vs topiramate), GLP-1 in dementia incidence (20–35% reduction across 2+ million diabetics), and the broader living systematic review of GLP-1 across Alzheimer's, Parkinson's, multiple sclerosis, and stroke.
Other neurology threads: Sanofi's Tzield in T1D-related autoimmunity, Briacell's Bria-IMT in HER2 breast cancer brain metastases, Fedora's lactivicin work on CNS-tropic gram-negatives, and academic programs on neuropeptides and ion-channel-targeted peptides.
Stories here cover the AAN data, registry analyses, and the peptide-neurology pipeline. See #cgrp, #alzheimers, and #parkinsons for narrower threads.
Researchers at Harbin Medical University reported in CNS Neuroscience & Therapeutics, published online October 1, 2026, that B9, a peptide derived from the viral protein apoptin, lowered seizure susceptibility, reduced epileptiform activity on EEG, and improved spatial learning and memory in mouse models of acute seizures and kainic acid-induced temporal lobe epilepsy. The team traced the effect to B9 suppressing the heat shock protein HSPA1A and freeing the protein AP2B1, which preserved the glutamate receptor subunit GluA2 and limited calcium overload in neurons; knocking down AP2B1 erased B9's benefits. The findings come from mice only.
Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.